Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by fluctuating weakness of skeletal (voluntary) muscles. The condition arises from a defect in the transmission of nerve impulses at the neuromuscular junction due to the presence of autoantibodies. The experts at Citeline have curated a new disease intelligence report specific to Myasthenia Gravis available for purchase now. This PDF report with accompanying patient-based excel forecast was created to answer key questions such as:

• How much market share will Soliris continue to capture?
• What is the addressable patient population within Myasthenia Gravis?
• What are the unmet needs within this space?
• What is the landscape of pipeline drugs- who do we need to be paying attention to?
• What are the strengths and weaknesses of ALXN1720 (or other drugs!) in Myasthenia Gravis?
• What future trends are analysts seeing for these patients?

To learn more, please contact us here for a table of contents!